Search:
You do not have permission to access this chart.
Please Sign Up or Login
News for Satsuma Pharmaceuticals, Inc. (STSA)
minutes ago | Banggood.com
58 minutes ago | Aliexpress.com
Satsuma Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Business Highlights
4 days ago | GlobeNewsWire
2 weeks ago | GlobeNewsWire
a month ago | GlobeNewsWire
a month ago | Pulse2
a month ago | GlobeNewsWire
3 months ago | GlobeNewsWire
3 months ago | Zacks Investment Research
4 months ago | GlobeNewsWire
5 months ago | Benzinga
5 months ago | GlobeNewsWire
About:
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops a novel therapeutic product for the acute treatment of migraine. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in Phase III clinical trials and can be self-administered with a proprietary pre-filled, single-use, and nasal delivery device. The company was founded in 2016 and is headquartered in South San Francisco, California.
Sector:
HealthcareIndustry:
BiotechnologyEmployees:
20Address:
Satsuma Pharmaceuticals, Inc. 400 Oyster Point Boulevard Suite 221 South San Francisco CA 94080 United StatesWebsite:
Home